During a comprehensive medication review, you see a 71-year-old woman with COPD, osteoporosis, hypothyroidism, and gastro-oesophageal reflux disease. She takes tiotropium, salmeterol/fluticasone combination inhaler, alendronic acid 70mg weekly, calcium and vitamin D, levothyroxine 100mcg daily, and omeprazole 20mg daily (started 4 years ago for reflux symptoms which resolved after 6 months). Recent bone density scan shows stable T-scores. What is the primary concern regarding her long-term proton pump inhibitor use in the context of her other conditions?
Q142
A 69-year-old man with hypertension, type 2 diabetes, stage 3a CKD, and a history of peptic ulcer disease (treated 3 years ago) attends for review. He takes ramipril, amlodipine, metformin, atorvastatin, and aspirin 75mg daily (started for primary prevention 8 years ago when he was found to have impaired glucose tolerance). His blood pressure is 132/78 mmHg, BMI 28 kg/m², HbA1c 51 mmol/L, total cholesterol 4.2 mmol/L, eGFR 52 ml/min/1.73m². He has never had cardiovascular disease. According to current evidence-based guidance, what is the MOST appropriate management of his aspirin?
Q143
You are conducting a structured medication review using the Beers Criteria for a 74-year-old man with benign prostatic hyperplasia, chronic constipation, glaucoma (well-controlled with eye drops), and anxiety. He takes tamsulosin, movicol, latanoprost eye drops, and has been taking amitriptyline 25mg nightly for 5 years for anxiety (started by previous GP). He reports the amitriptyline helps him sleep but mentions increasing difficulty passing urine. Which statement BEST describes the application of the Beers Criteria to this patient's medication regimen?
Q144
A 77-year-old woman with dementia, type 2 diabetes, ischaemic heart disease, and recurrent falls is brought by her care home manager for medication review. She takes donepezil, memantine, aspirin, atorvastatin, bisoprolol, amlodipine, metformin, and gliclazide. Her recent HbA1c is 42 mmol/mol, blood pressure 118/70 mmHg lying and 95/60 mmHg standing. She has had three documented falls in the past two months with no clear precipitant. Applying the principles of comprehensive geriatric assessment and deprescribing, which medication change would provide the GREATEST reduction in falls risk while maintaining essential treatment?
Q145
You are reviewing a 70-year-old man with type 2 diabetes, chronic kidney disease stage 3b, heart failure with preserved ejection fraction (HFpEF), and gout. His medications include metformin 500mg twice daily, empagliflozin 10mg daily, ramipril 10mg daily, furosemide 40mg daily, and allopurinol 100mg daily. Recent blood tests show: eGFR 38 ml/min/1.73m², HbA1c 58 mmol/mol, uric acid 420 μmol/L (had gout attack 2 months ago). What represents the MOST evidence-based medication optimization for this patient?
Q146
A 75-year-old woman attends with her daughter who is concerned about her mother's memory. The patient has type 2 diabetes, hypertension, atrial fibrillation, and osteoarthritis. Her current medications include metformin, gliclazide, ramipril, bisoprolol, apixaban, and oxybutynin 5mg twice daily (started 6 months ago for urinary frequency). On cognitive screening, her MoCA score is 22/30 with particular deficits in attention and short-term memory. Physical examination is unremarkable. What medication change is MOST likely to improve her cognitive function?
Q147
During a practice-based audit of patients with multimorbidity, you identify a 68-year-old man with COPD, ischaemic heart disease, type 2 diabetes, and depression taking 11 regular medications. His recent spirometry shows FEV1 45% predicted. He is on maximum inhaled therapy including LABA/LAMA/ICS triple therapy, and has had two moderate COPD exacerbations in the past year requiring oral corticosteroids. His medications also include aspirin, atorvastatin, bisoprolol, ramipril, metformin, sitagliptin, and sertraline. According to current NICE guidance on multimorbidity, what is the MOST appropriate next step in his management?
Q148
A 72-year-old woman with chronic kidney disease stage 4 (eGFR 22 ml/min/1.73m²), type 2 diabetes, and heart failure with reduced ejection fraction presents for review. Her current medications include insulin, furosemide, spironolactone, bisoprolol, and atorvastatin. Recent bloods show potassium 5.8 mmol/L (repeat confirmed), HbA1c 64 mmol/mol, and bicarbonate 18 mmol/L. She is asymptomatic. Which medication adjustment represents the MOST appropriate immediate management?
Q149
You are conducting a structured medication review for a 79-year-old man with Parkinson's disease, type 2 diabetes, benign prostatic hyperplasia, and insomnia. His medications include co-careldopa, pramipexole, metformin, sitagliptin, tamsulosin, and zopiclone 7.5mg nightly (prescribed 18 months ago). He reports his sleep has not improved and he feels unsteady in the mornings. What is the MOST appropriate management of his zopiclone?
Q150
A 67-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and depression attends for a comprehensive medication review. She takes methotrexate 15mg weekly, folic acid, alendronic acid 70mg weekly, calcium and vitamin D, amlodipine, and sertraline. She mentions that she occasionally takes ibuprofen purchased over-the-counter for joint pain. What is the MOST concerning aspect of her medication use requiring immediate action?
Chronic Disease Management UK Medical PG Practice Questions and MCQs
Question 141: During a comprehensive medication review, you see a 71-year-old woman with COPD, osteoporosis, hypothyroidism, and gastro-oesophageal reflux disease. She takes tiotropium, salmeterol/fluticasone combination inhaler, alendronic acid 70mg weekly, calcium and vitamin D, levothyroxine 100mcg daily, and omeprazole 20mg daily (started 4 years ago for reflux symptoms which resolved after 6 months). Recent bone density scan shows stable T-scores. What is the primary concern regarding her long-term proton pump inhibitor use in the context of her other conditions?
A. Reduced levothyroxine absorption leading to suboptimal thyroid hormone replacement
B. Increased risk of COPD exacerbations through altered gastric pH and bacterial overgrowth
C. Reduced calcium absorption potentially compromising osteoporosis management and fracture prevention (Correct Answer)
D. Drug interaction with inhaled corticosteroids increasing pneumonia risk
E. Impaired vitamin B12 absorption leading to peripheral neuropathy
Explanation: ***Reduced calcium absorption potentially compromising osteoporosis management and fracture prevention***- Long-term **Proton Pump Inhibitor (PPI)** use significantly reduces **gastric acid** production, which is crucial for the absorption of certain forms of calcium, particularly **calcium carbonate**.- In a patient with **osteoporosis** receiving **alendronic acid** and **calcium/vitamin D** supplementation, impaired calcium absorption can hinder bone mineralization and increase the risk of **fragility fractures**, despite stable T-scores currently.*Reduced levothyroxine absorption leading to suboptimal thyroid hormone replacement*- **Levothyroxine** absorption can be reduced by PPIs due to increased gastric pH, as an acidic environment optimizes its dissolution and absorption.- While a valid concern, this interaction is typically managed by monitoring **TSH levels** and adjusting the levothyroxine dose; it's often considered less acute than the direct impact on bone health in an osteoporosis patient already on bone-protective therapy.*Increased risk of COPD exacerbations through altered gastric pH and bacterial overgrowth*- Long-term PPI use has been associated with an increased risk of **community-acquired pneumonia** due to altered gastric pH leading to bacterial overgrowth and aspiration.- However, a direct, strong, and consistently proven link to increased **COPD exacerbations** specifically is less established compared to the clear impact on calcium absorption in osteoporosis.*Drug interaction with inhaled corticosteroids increasing pneumonia risk*- There is no direct pharmacokinetic or pharmacodynamic **drug-drug interaction** between PPIs and **inhaled corticosteroids (ICS)** that would synergistically increase pneumonia risk.- While ICS themselves are a known risk factor for pneumonia in COPD patients, the PPI does not compound this risk through a direct interaction with the ICS medication.*Impaired vitamin B12 absorption leading to peripheral neuropathy*- Chronic PPI use can lead to **vitamin B12 deficiency** due to inhibition of gastric acid and pepsin, which are necessary to release B12 from food proteins for absorption.- While a significant long-term concern that can lead to neurological symptoms like **peripheral neuropathy**, the immediate and primary concern in an elderly patient with **osteoporosis** on bone-protective therapy is the direct impact on calcium absorption and fracture risk.
Question 142: A 69-year-old man with hypertension, type 2 diabetes, stage 3a CKD, and a history of peptic ulcer disease (treated 3 years ago) attends for review. He takes ramipril, amlodipine, metformin, atorvastatin, and aspirin 75mg daily (started for primary prevention 8 years ago when he was found to have impaired glucose tolerance). His blood pressure is 132/78 mmHg, BMI 28 kg/m², HbA1c 51 mmol/L, total cholesterol 4.2 mmol/L, eGFR 52 ml/min/1.73m². He has never had cardiovascular disease. According to current evidence-based guidance, what is the MOST appropriate management of his aspirin?
A. Continue aspirin as he has multiple cardiovascular risk factors including diabetes and CKD
B. Stop aspirin as he has no cardiovascular disease and bleeding risk outweighs benefit in primary prevention (Correct Answer)
C. Continue aspirin but add a proton pump inhibitor given history of peptic ulcer disease
D. Switch aspirin to clopidogrel which has a better safety profile for primary prevention
E. Reduce aspirin to 75mg on alternate days to minimize bleeding risk while maintaining cardiovascular protection
Explanation: ***Stop aspirin as he has no cardiovascular disease and bleeding risk outweighs benefit in primary prevention***
- In **primary prevention**, major clinical trials (e.g., **ASCEND**, **ASPREE**, **ARRIVE**) consistently demonstrate that the modest **cardiovascular benefits** of aspirin are generally outweighed by a significant increase in **major bleeding** events.
- This patient, without established **cardiovascular disease**, has an increased **bleeding risk** due to his age and history of **peptic ulcer disease**, making aspirin discontinuation the most appropriate management.
*Continue aspirin as he has multiple cardiovascular risk factors including diabetes and CKD*
- Despite multiple **cardiovascular risk factors** like **diabetes** and **CKD**, current evidence-based guidelines do not recommend aspirin for **primary prevention** due to the unfavorable risk-benefit profile, particularly the increased **bleeding risk**.
- His cardiovascular risk is adequately managed with existing medications like **statins**, **ACE inhibitors**, and **metformin**, which have proven benefits in primary prevention without the added bleeding burden of aspirin.
*Continue aspirin but add a proton pump inhibitor given history of peptic ulcer disease*
- While a **proton pump inhibitor (PPI)** can mitigate the **gastrointestinal bleeding risk** associated with aspirin, it does not justify the use of aspirin for **primary prevention** when there is no established **cardiovascular disease**.
- Adding a PPI introduces further **polypharmacy** without addressing the fundamental lack of indication for aspirin in this primary prevention setting.
*Switch aspirin to clopidogrel which has a better safety profile for primary prevention*
- **Clopidogrel** is primarily indicated for **secondary prevention** of cardiovascular events or in specific high-risk conditions, not for routine **primary prevention** in patients without established disease.
- Like aspirin, clopidogrel also carries a **bleeding risk**, and there is no evidence to support its use as a safer or more effective alternative for primary prevention.
*Reduce aspirin to 75mg on alternate days to minimize bleeding risk while maintaining cardiovascular protection*
- There is no clinical evidence or guideline support for **alternate-day dosing** of aspirin as an effective strategy to minimize bleeding risk while maintaining cardiovascular protection for **primary prevention**.
- Even reduced or intermittent dosing of aspirin still inhibits **platelet function** and carries a risk of **mucosal injury**, failing to eliminate the bleeding danger in high-risk patients.
Question 143: You are conducting a structured medication review using the Beers Criteria for a 74-year-old man with benign prostatic hyperplasia, chronic constipation, glaucoma (well-controlled with eye drops), and anxiety. He takes tamsulosin, movicol, latanoprost eye drops, and has been taking amitriptyline 25mg nightly for 5 years for anxiety (started by previous GP). He reports the amitriptyline helps him sleep but mentions increasing difficulty passing urine. Which statement BEST describes the application of the Beers Criteria to this patient's medication regimen?
A. Amitriptyline is potentially inappropriate due to its anticholinergic effects worsening urinary retention and constipation (Correct Answer)
B. Tamsulosin should be stopped as alpha-blockers are potentially inappropriate in elderly males with glaucoma
C. Movicol is potentially inappropriate as osmotic laxatives increase electrolyte disturbance risk in elderly patients
D. Latanoprost is potentially inappropriate as prostaglandin analogues worsen urinary symptoms
E. All current medications are appropriate according to Beers Criteria given documented clinical benefit
Explanation: ***Amitriptyline is potentially inappropriate due to its anticholinergic effects worsening urinary retention and constipation***- **Amitriptyline** is a Tricyclic Antidepressant (TCA) with strong **anticholinergic properties**, which are explicitly flagged in the **Beers Criteria** as potentially inappropriate for older adults.- These effects directly exacerbate this patient's pre-existing **benign prostatic hyperplasia (BPH)** and **chronic constipation**, likely contributing to his worsening urinary symptoms.*Tamsulosin should be stopped as alpha-blockers are potentially inappropriate in elderly males with glaucoma*- **Tamsulosin** is a selective alpha-1 blocker and remains a standard, appropriate treatment for **BPH** symptoms in older men.- It is not contraindicated in **glaucoma**; however, clinicians should be aware of **Intraoperative Floppy Iris Syndrome (IFIS)** if the patient undergoes cataract surgery.*Movicol is potentially inappropriate as osmotic laxatives increase electrolyte disturbance risk in elderly patients*- **Movicol (Macrogol)** is an osmotic laxative generally considered safe and effective for **chronic constipation** in the elderly.- Unlike stimulant laxatives or certain saline enemas, it does not carry a high risk of **electrolyte disturbances** when used at standard maintenance doses.*Latanoprost is potentially inappropriate as prostaglandin analogues worsen urinary symptoms*- **Latanoprost** is a first-line topical treatment for **glaucoma** and is considered highly appropriate due to its localized action.- There is no clinical evidence or pharmacological mechanism suggesting that **prostaglandin analogues** administered as eye drops worsen **lower urinary tract symptoms**.*All current medications are appropriate according to Beers Criteria given documented clinical benefit*- This statement is incorrect because **amitriptyline** is a well-documented **Potentially Inappropriate Medication (PIM)** in the elderly due to high risk of adverse effects.- Clinical benefit for sleep or anxiety does not override the **Beers Criteria** recommendation to avoid TCAs when safer alternatives like SSRIs or non-pharmacological therapies exist.
Question 144: A 77-year-old woman with dementia, type 2 diabetes, ischaemic heart disease, and recurrent falls is brought by her care home manager for medication review. She takes donepezil, memantine, aspirin, atorvastatin, bisoprolol, amlodipine, metformin, and gliclazide. Her recent HbA1c is 42 mmol/mol, blood pressure 118/70 mmHg lying and 95/60 mmHg standing. She has had three documented falls in the past two months with no clear precipitant. Applying the principles of comprehensive geriatric assessment and deprescribing, which medication change would provide the GREATEST reduction in falls risk while maintaining essential treatment?
A. Stop gliclazide and accept slightly higher HbA1c target given fall risk and tight glycaemic control
B. Stop amlodipine given orthostatic hypotension and already achieving blood pressure target (Correct Answer)
C. Stop both donepezil and memantine as cognitive medications increase falls through dizziness
D. Stop aspirin as the bleeding risk from falls outweighs cardiovascular benefit
E. Reduce bisoprolol dose by half to minimize bradycardia-related falls
Explanation: ***Stop amlodipine given orthostatic hypotension and already achieving blood pressure target***- The patient has documented **orthostatic hypotension** (a systolic drop of 23 mmHg from 118/70 to 95/60 mmHg), which is a significant modifiable **risk factor for falls** in the elderly.- Amlodipine is a **vasodilatory agent** that directly contributes to hypotension and orthostasis; her blood pressure is already well-controlled, making its removal a primary intervention to reduce falls.*Stop gliclazide and accept slightly higher HbA1c target given fall risk and tight glycaemic control*- While her **HbA1c of 42 mmol/mol** is low for a frail elderly patient, there is no clinical evidence of **hypoglycemia** being the primary trigger for her falls.- Though reducing medication burden is appropriate, stopping an antihypertensive agent provides a more direct intervention for her proven **postural drop**.*Stop both donepezil and memantine as cognitive medications increase falls through dizziness*- Donepezil and memantine provide important **cognitive benefits** in dementia and are not typically the primary drivers of gait instability compared to cardiovascular drugs.- Abruptly stopping these medications can lead to a significant **decline in cognitive function** and increased behavioral symptoms, without a guaranteed or immediate reduction in falls risk.*Stop aspirin as the bleeding risk from falls outweighs cardiovascular benefit*- There is no mention of **anticoagulation complications** or severe bleeding events that would currently necessitate stopping secondary prevention for her **ischaemic heart disease**.- Aspirin does not cause hemodynamic instability or dizziness, so its cessation would not directly prevent the mechanics of her **recurrent falls**.*Reduce bisoprolol dose by half to minimize bradycardia-related falls*- Bisoprolol is essential for managing her **ischaemic heart disease**, and there is no documentation of symptomatic **bradycardia** in the patient's presentation.- While beta-blockers can contribute to hypotension, the significant **orthostatic drop** is more characteristically exacerbated by pure vasodilators like calcium channel blockers (amlodipine) than by bisoprolol.
Question 145: You are reviewing a 70-year-old man with type 2 diabetes, chronic kidney disease stage 3b, heart failure with preserved ejection fraction (HFpEF), and gout. His medications include metformin 500mg twice daily, empagliflozin 10mg daily, ramipril 10mg daily, furosemide 40mg daily, and allopurinol 100mg daily. Recent blood tests show: eGFR 38 ml/min/1.73m², HbA1c 58 mmol/mol, uric acid 420 μmol/L (had gout attack 2 months ago). What represents the MOST evidence-based medication optimization for this patient?
A. Stop metformin as eGFR is below 45 ml/min/1.73m² and continue empagliflozin alone
B. Increase allopurinol to 300mg daily to achieve target uric acid <360 μmol/L (Correct Answer)
C. Stop empagliflozin due to increased genital infection risk in CKD and optimize metformin
D. Add spironolactone as evidence shows mortality benefit in HFpEF
E. Switch ramipril to sacubitril-valsartan for improved heart failure outcomes
Explanation: ***Increase allopurinol to 300mg daily to achieve target uric acid <360 μmol/L***- The patient's uric acid is **420 μmol/L** and he recently had a gout attack, making the **treat-to-target** goal for **uric acid <360 μmol/L** (or lower for severe gout) crucial to prevent future attacks.- Allopurinol should be **titrated upwards** gradually, even in **CKD stage 3b**, to reach the target, as the current 100mg dose is subtherapeutic and dose adjustments are safe with monitoring. *Stop metformin as eGFR is below 45 ml/min/1.73m² and continue empagliflozin alone*- Metformin typically requires a **dose reduction** (to a maximum of 1000mg/day) when **eGFR is between 30-45 ml/min/1.73m²**, which the current 500mg BID dose adheres to.- Complete cessation of metformin is generally recommended only when **eGFR falls below 30 ml/min/1.73m²** due to increased risk of lactic acidosis. *Stop empagliflozin due to increased genital infection risk in CKD and optimize metformin*- **SGLT2 inhibitors** like empagliflozin provide significant and evidence-based **cardiorenal protection** in patients with **CKD** and **HFpEF** (e.g., EMPA-KIDNEY and EMPEROR-Preserved trials).- The benefits of empagliflozin in reducing cardiovascular events, heart failure hospitalizations, and kidney disease progression typically **outweigh the manageable risk** of genital infections. *Add spironolactone as evidence shows mortality benefit in HFpEF*- The **TOPCAT trial** did not demonstrate a significant **mortality benefit** for spironolactone in HFpEF, unlike in HFrEF, making its routine use for mortality reduction less established in this population.- Adding spironolactone to ramipril in a patient with **CKD stage 3b** significantly increases the risk of **hyperkalemia**, requiring very careful monitoring or contraindication. *Switch ramipril to sacubitril-valsartan for improved heart failure outcomes*- **Sacubitril-valsartan (ARNI)** is primarily indicated and has strong evidence for improving outcomes in heart failure with **reduced ejection fraction (HFrEF)**.- The **PARAGON-HF trial** in HFpEF did not meet its primary endpoint for a significant reduction in heart failure hospitalizations or cardiovascular death across the overall study population, limiting its widespread recommendation for HFpEF.
Question 146: A 75-year-old woman attends with her daughter who is concerned about her mother's memory. The patient has type 2 diabetes, hypertension, atrial fibrillation, and osteoarthritis. Her current medications include metformin, gliclazide, ramipril, bisoprolol, apixaban, and oxybutynin 5mg twice daily (started 6 months ago for urinary frequency). On cognitive screening, her MoCA score is 22/30 with particular deficits in attention and short-term memory. Physical examination is unremarkable. What medication change is MOST likely to improve her cognitive function?
A. Stop gliclazide and optimize metformin to prevent hypoglycaemia-related cognitive impairment
B. Reduce bisoprolol dose as beta-blockers can cause cognitive slowing in elderly patients
C. Stop oxybutynin due to its anticholinergic effects on cognition (Correct Answer)
D. Switch apixaban to warfarin to improve cerebral perfusion through better anticoagulation control
E. Add donepezil to counteract early cognitive decline
Explanation: ***Stop oxybutynin due to its anticholinergic effects on cognition***- **Oxybutynin** is a potent **anticholinergic** agent that readily crosses the blood-brain barrier and is strongly associated with **cognitive impairment**, delirium, and memory deficits in elderly patients.- The recent initiation of oxybutynin (6 months ago) coincides with the onset of the patient's cognitive concerns, making it the most likely reversible cause.*Stop gliclazide and optimize metformin to prevent hypoglycaemia-related cognitive impairment*- While **hypoglycemia** can acutely impair cognitive function, there is no clinical evidence in the patient's presentation (e.g., blood glucose levels, symptoms) to suggest this is the primary cause of her chronic cognitive decline.- Gliclazide is a standard medication for Type 2 Diabetes, and discontinuing it without specific indications of hypoglycemia would not address the more prominent reversible cause of cognitive impairment.*Reduce bisoprolol dose as beta-blockers can cause cognitive slowing in elderly patients*- **Bisoprolol** is a hydrophilic beta-blocker, meaning it has limited penetration into the central nervous system and is less likely to cause **cognitive side effects** compared to lipophilic beta-blockers.- Given her history of **hypertension** and **atrial fibrillation**, bisoprolol serves important cardiovascular functions and is unlikely to be the primary driver of her specific cognitive deficits.*Switch apixaban to warfarin to improve cerebral perfusion through better anticoagulation control*- **Apixaban**, a direct oral anticoagulant (DOAC), is often preferred over **warfarin** in elderly patients due to its more predictable anticoagulant effect and lower risk of bleeding, particularly intracranial hemorrhage.- Switching to warfarin would increase monitoring burden and does not offer any proven benefit for **cerebral perfusion** or cognitive function compared to apixaban for stroke prevention in atrial fibrillation.*Add donepezil to counteract early cognitive decline*- Adding an **acetylcholinesterase inhibitor** like donepezil is generally not recommended before evaluating and eliminating all **reversible causes** of cognitive impairment.- Donepezil works by increasing **acetylcholine** levels, so administering it while the patient is still taking **oxybutynin** (an anticholinergic) would result in pharmacological antagonism, potentially negating donepezil's intended effect.
Question 147: During a practice-based audit of patients with multimorbidity, you identify a 68-year-old man with COPD, ischaemic heart disease, type 2 diabetes, and depression taking 11 regular medications. His recent spirometry shows FEV1 45% predicted. He is on maximum inhaled therapy including LABA/LAMA/ICS triple therapy, and has had two moderate COPD exacerbations in the past year requiring oral corticosteroids. His medications also include aspirin, atorvastatin, bisoprolol, ramipril, metformin, sitagliptin, and sertraline. According to current NICE guidance on multimorbidity, what is the MOST appropriate next step in his management?
A. Refer to respiratory specialist for consideration of azithromycin prophylaxis
B. Initiate immediate deprescribing plan to reduce pill burden below 10 medications
C. Arrange holistic medication and care review focused on patient priorities and quality of life (Correct Answer)
D. Add roflumilast to reduce exacerbation frequency in severe COPD
E. Refer to community pharmacy for compliance aids to manage polypharmacy
Explanation: ***Arrange holistic medication and care review focused on patient priorities and quality of life***- **NICE guideline NG56** recommends a patient-centered approach for individuals with **multimorbidity** and high **treatment burden**, specifically focusing on what matters most to the patient.- This review aims to identify **treatment goals**, assess the impact of symptoms on daily life, and utilize **shared decision-making** rather than following separate disease-specific protocols.*Refer to respiratory specialist for consideration of azithromycin prophylaxis*- While clinically indicated for frequent COPD exacerbations, this is a **disease-specific** step that ignores the broader context of **multimorbidity** management.- Adding a chronic antibiotic increases the **pill burden** and potential for side effects/interactions in a patient already on 11 medications.*Initiate immediate deprescribing plan to reduce pill burden below 10 medications*- Deprescribing should be a result of a **holistic review** rather than an arbitrary target based on the total number of medications.- A rush to stop medications without a **clinical assessment** of their benefits could worsen the patient's underlying conditions like **IHD** or **depression**.*Add roflumilast to reduce exacerbation frequency in severe COPD*- Roflumilast can be considered for chronic bronchitis in severe COPD, but adding more drugs addresses only one condition and potentially increases **polypharmacy** issues.- **NICE multimorbidity guidance** prioritizes reducing treatment burden over simply adding further pharmacological interventions.*Refer to community pharmacy for compliance aids to manage polypharmacy*- **Compliance aids** (e.g., dosette boxes) may help with administration but do not address the appropriateness of the medications or the **patient's priorities**.- The primary issue is the complexity of managing multiple conditions, which requires a **clinical review** by the primary care team rather than just a technical aid.
Question 148: A 72-year-old woman with chronic kidney disease stage 4 (eGFR 22 ml/min/1.73m²), type 2 diabetes, and heart failure with reduced ejection fraction presents for review. Her current medications include insulin, furosemide, spironolactone, bisoprolol, and atorvastatin. Recent bloods show potassium 5.8 mmol/L (repeat confirmed), HbA1c 64 mmol/mol, and bicarbonate 18 mmol/L. She is asymptomatic. Which medication adjustment represents the MOST appropriate immediate management?
A. Stop spironolactone and recheck potassium in one week (Correct Answer)
B. Reduce insulin dose to prevent further hyperkalaemia
C. Stop atorvastatin due to increased rhabdomyolysis risk in CKD
D. Increase furosemide to enhance potassium excretion
E. Add calcium resonium to bind excess potassium while continuing current medications
Explanation: ***Stop spironolactone and recheck potassium in one week*** - The patient has **hyperkalaemia (5.8 mmol/L)** and **CKD Stage 4** (eGFR 22 ml/min/1.73m²); **spironolactone**, a potassium-sparing diuretic, is a major contributor and should be discontinued immediately. - Guidelines for **HFrEF** management advise extreme caution or avoidance of **Mineralocorticoid Receptor Antagonists** when the eGFR is below 30 mL/min/1.73m² due to the high risk of life-threatening arrhythmias. *Reduce insulin dose to prevent further hyperkalaemia* - **Insulin** actually drives potassium into cells, effectively **lowering serum potassium**; reducing the dose would likely worsen hyperkalaemia and lead to hyperglycaemia. - While insulin deficiency can contribute to hyperkalaemia, reducing exogenous insulin would be counterproductive to managing elevated potassium. *Stop atorvastatin due to increased rhabdomyolysis risk in CKD* - While **statin** metabolism can be altered in renal impairment, **atorvastatin** does not require dose adjustment in CKD and is not the cause of the acute electrolyte abnormality. - **Cardiovascular protection** is vital in diabetic CKD patients, and there is no clinical evidence of myopathy or rhabdomyolysis in this asymptomatic patient to warrant discontinuation. *Increase furosemide to enhance potassium excretion* - Although **loop diuretics** like furosemide increase potassium excretion, this is an indirect treatment that does not address the **offending medication** (spironolactone) currently causing the elevation. - Increasing furosemide without stopping spironolactone carries a risk of **acute kidney injury** and dehydration in a patient with already advanced CKD. *Add calcium resonium to bind excess potassium while continuing current medications* - **Cation-exchange resins** like calcium resonium are generally used as a bridge to other therapies for severe or symptomatic hyperkalaemia and are poorly tolerated due to **gastrointestinal side effects**. - The primary management of drug-induced hyperkalaemia must always be the **withdrawal of the causative medication** rather than adding further pharmacological binding agents.
Question 149: You are conducting a structured medication review for a 79-year-old man with Parkinson's disease, type 2 diabetes, benign prostatic hyperplasia, and insomnia. His medications include co-careldopa, pramipexole, metformin, sitagliptin, tamsulosin, and zopiclone 7.5mg nightly (prescribed 18 months ago). He reports his sleep has not improved and he feels unsteady in the mornings. What is the MOST appropriate management of his zopiclone?
A. Continue zopiclone as insomnia is common in Parkinson's disease and requires ongoing treatment
B. Increase zopiclone dose to 10mg as current dose is sub-therapeutic
C. Initiate gradual withdrawal as he has been on zopiclone beyond recommended duration (Correct Answer)
D. Switch to a benzodiazepine which has a better safety profile in Parkinson's disease
E. Add melatonin while continuing zopiclone for enhanced sleep benefit
Explanation: ***Initiate gradual withdrawal as he has been on zopiclone beyond recommended duration***- **Z-drugs** should only be used for short periods, typically **2-4 weeks**, to prevent **tolerance**, dependence, and sedation-related adverse effects such as **falls**.- This patient's **morning unsteadiness** and long-term use (18 months) without benefit clearly indicate the need for **gradual withdrawal** to improve safety and mobility.*Continue zopiclone as insomnia is common in Parkinson's disease and requires ongoing treatment*- While insomnia is prevalent in **Parkinson's disease**, chronic use of **hypnotics** like zopiclone is not a recommended long-term management strategy.- Prolonged use in elderly patients significantly elevates the risk of **cognitive impairment**, **daytime somnolence**, and **hip fractures** due to nocturnal or morning instability.*Increase zopiclone dose to 10mg as current dose is sub-therapeutic*- Increasing the dose would exacerbate the patient's existing **unsteadiness** and heighten the risk of severe confusion or **respiratory depression**.- A dose of **7.5mg** is already the maximum recommended; in elderly individuals, a lower starting dose of **3.75mg** is typically advised.*Switch to a benzodiazepine which has a better safety profile in Parkinson's disease*- **Benzodiazepines** do not possess a better safety profile than Z-drugs and carry similar risks of **daytime somnolence**, **ataxia**, and increased **fall risk**.- Substituting one sedating agent for another (a "prescribing cascade" or "flip-flop") fails to address the underlying problem of **medication-induced instability** and polypharmacy.*Add melatonin while continuing zopiclone for enhanced sleep benefit*- Adding **melatonin** while continuing zopiclone increases **polypharmacy** and the potential for drug-drug interactions in this complex elderly patient.- The management priority should be to deprescribe **potentially inappropriate medications** (PIMs) like zopiclone rather than introducing additional sedatives.
Question 150: A 67-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and depression attends for a comprehensive medication review. She takes methotrexate 15mg weekly, folic acid, alendronic acid 70mg weekly, calcium and vitamin D, amlodipine, and sertraline. She mentions that she occasionally takes ibuprofen purchased over-the-counter for joint pain. What is the MOST concerning aspect of her medication use requiring immediate action?
A. Regular NSAID use with methotrexate increases haematological toxicity risk
B. Alendronic acid may not be absorbed effectively with calcium supplementation
C. Sertraline combined with NSAIDs significantly increases upper gastrointestinal bleeding risk (Correct Answer)
D. Methotrexate dose is too high for a patient also taking an NSAID
E. Folic acid should be taken on the same day as methotrexate for optimal effect
Explanation: ***Sertraline combined with NSAIDs significantly increases upper gastrointestinal bleeding risk*** - **SSRIs** (like sertraline) interfere with serotonin uptake in platelets, which impairs **platelet aggregation** and weakens the gastric mucosal defense. - When combined with **NSAIDs**, the risk of **upper gastrointestinal bleeding** increases synergistically (estimated 6-fold increase), requiring immediate cessation or **PPI co-prescription**. *Regular NSAID use with methotrexate increases haematological toxicity risk* - NSAIDs can reduce the **renal clearance** of methotrexate, potentially increasing its systemic levels and toxic effects. - While clinically relevant, this interaction is generally manageable with **blood monitoring** and is considered less of an immediate safety threat than a major GI bleed at this dose. *Alendronic acid may not be absorbed effectively with calcium supplementation* - **Calcium carbonate** can bind to bisphosphonates in the gut, significantly reducing the **bioavailability** and efficacy of alendronic acid. - This is a significant **counseling point** regarding the timing of doses (separating them by at least 2 hours), but it does not represent an acute safety emergency. *Methotrexate dose is too high for a patient also taking an NSAID* - A weekly dose of **15mg methotrexate** is a standard maintenance dose for **rheumatoid arthritis** and is not considered inherently excessive. - The presence of an NSAID necessitates careful **monitoring of FBC and LFTs** but does not automatically mandate a dose reduction of the DMARD. *Folic acid should be taken on the same day as methotrexate for optimal effect* - Taking **folic acid** on the same day as methotrexate can potentially reduce the **therapeutic efficacy** of the drug by competing for enzymes. - Guidelines usually recommend taking folic acid at least **24 hours after** the methotrexate dose to mitigate side effects like nausea and oral ulcers.
